Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

Researchers at the School of Chinese Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have found that ...

When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

Brazil is experiencing a regulatory revolution that is fundamentally transforming its medical device clinical trial landscape ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...

Researchers in France have developed an antibody that blocks AMH, reversing PCOS symptoms in mice and opening the door to future human trials.